Category: St. Jude Medical
Boston Scientific, Medtronic and Covidien take millions in write-downs on their renal denervation assets after the failure of Medtronic's Symplicity-3 trial.
Two perforation-related deaths and 4 additional adverse events temporarily derail enrollment in St. Jude Medical's European Nanostim registry as the company evaluates the patient injuries.
Updated May 12, 2014, at 5:30 p.m. with confirmation from St. Jude Medical.
Medtech's biggest players release a slew of new reports at this year's Heart Rhythm Society conference, with Medtronic data on preventive shocks for ICD patients, lowered mortality for patients remotely monitored with Boston Scientific's LATITUDE system, and more.
Researchers at this year's Heart Rhythm Society conference are still struggling to figure out the best way to manage patients still implanted with St. Jude Medical's recalled Riata defibrillator leads, but the company won some hearts with strong findings for its next-generation Optim-coated devices.
Here's a look at some of the top legal news stories for medical device companies this week: Justice Dept. probes St. Jude for potential False Claims, kickbacks violations; More secret human studies uncovered in Myxo ring inquiry; Medtech manufacturer fleeced Stryker, says former exec; FDA morcellator warning spurs lawsuit against J&J; NuVasive claims win in patent spat with Cadwell Labs
, Dept. of Justice (DOJ)
, Edwards Lifesciences
, Ethicon Endo-Surgery
, Ferry Machine Corp.
, Food & Drug Administration (FDA)
, Johnson & Johnson
, St. Jude Medical
, Stryker Corp.
, U.S. Senate
The battle over battery life was a big part of this year's Heart Rhythm Society conference, but who came out on top?
A string of presentations and poster sessions during this week's Heart Rhythm conference pitted device makers against each other in the battle for battery superiority.
St. Jude Medical's game-changing Nanostim pacemaker still looks strong in 1-year results from an early study of heart failure patients.